Doustdar said Medicare coverage and the launch of Novo's new obesity pill should help gradually boost prescription volumes ...

The Trump administration says it will not move forward with a Biden proposal that Medicare cover anti-obesity drugs such as Novo Nordisk’s Wegovy and Zepbound from Eli Lilly. The drugs have been shown ...

As states cut Medicaid coverage for GLP-1 drugs, access to obesity treatment is increasingly tied to income—raising questions for both Medicaid and Medicare.

Thirteen states cover GLP-1 drugs through their Medicaid programs, and others are considering following suit (Mario Tama/Getty Images). President Donald Trump and Health Secretary Robert F. Kennedy Jr ...

Medicare covers treatments such as nutritional counseling and weight loss surgeries under certain conditions but not general weight loss programs or obesity medications. However, Medicare may expand ...

Please provide your email address to receive an email when new articles are posted on . A microsimulation model projected Medicare expenditures to increase $47.7 billion over 10 years with obesity ...

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration.

Novo Nordisk CEO Mike Doustdar tells CNBC that Medicare coverage for obesity treatments, as well as the launch of a new obesity pill, should help boost prescription volumes and offset lower prices.

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s. Congress is also considering such a move.

This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...

Novo Nordisk NVO CEO Mike Doustdar said the company aims to reach about 15 million new patients when Medicare begins covering ...